Please check your internet connection and try again.
## Potassium Chloride
### Overview
Potassium chloride (KCL) is an electrolyte replacement used to treat or prevent hypokalemia. It is available in oral and intravenous formulations.
### Primary Indications
* Treatment of hypokalemia.
* Prevention of hypokalemia in patients at risk.
### Adult Dosing
* **Oral:** Typical maintenance dose is 20-40 mEq per day, given in 1-2 divided doses. For severe hypokalemia, doses may range from 40-100 mEq per day, divided into 2-4 doses. Maximum single oral dose is typically 20 mEq. Higher doses may be used under close ECG and serum potassium monitoring.
* **Intravenous (IV):** Dosing is highly individualized and depends on the severity of hypokalemia and the patient's clinical status. Concentration should generally not exceed 40 mEq/L for peripheral IV administration, and infusion rates should not exceed 10-20 mEq/hour for peripheral IV and 40 mEq/hour for central venous access. Rapid IV infusion can be life-threatening. **Specific IV dosing protocols are critical and often vary by institution.**
### Pediatric Dosing
* **Oral:** Recommended daily intake varies by age. For treatment of hypokalemia, doses typically range from 1-4 mEq/kg/day, divided into 2-4 doses. Maximum daily dose is generally 100 mEq/day.
* **Intravenous (IV):** Dosing is highly individualized based on age, weight, and serum potassium levels. Maximum recommended infusion rate is typically 0.3-0.5 mEq/kg/hour (up to 1 mEq/kg/hour in dire emergencies with continuous cardiac monitoring). Maximum concentration for peripheral administration is usually 40 mEq/L. **Specific IV dosing protocols are critical and often vary by institution.**
### Dose Adjustments
* **Renal Impairment:** Use with caution. Reduced doses may be necessary. Monitor serum potassium closely.
* **Adrenal Insufficiency:** Increased risk of hyperkalemia. Use with caution and monitor serum potassium.
### Contraindications
* Hyperkalemia.
* Conditions where potassium retention is increased (e.g., severe renal impairment, untreated Addison's disease, severe burns, crush injuries, certain anemias).
* Anuria or oliguria.
* In patients receiving potassium-sparing diuretics concurrently, unless severe hypokalemia is present and serum potassium is closely monitored.
### Adverse Effects
* **Gastrointestinal:** Nausea, vomiting, diarrhea, abdominal pain, gastric irritation, ulceration, bleeding, perforation (especially with oral formulations).
* **Cardiovascular:** Arrhythmias, cardiac arrest (especially with rapid IV administration or hyperkalemia).
* **Other:** Hyperkalemia (manifesting as muscle weakness, fatigue, paresthesias, confusion, hypotension, bradycardia, cardiac arrest).
### Key Drug Interactions
* **Potassium-Sparing Diuretics (e.g., spironolactone, amiloride, triamterene) and ACE Inhibitors/ARBs:** Increased risk of hyperkalemia.
* **NSAIDs:** May impair potassium excretion, increasing the risk of hyperkalemia.
* **Heparin:** May impair potassium excretion, increasing the risk of hyperkalemia.
* **Digoxin:** Hyperkalemia can increase the risk of digoxin toxicity; hypokalemia can potentiate digoxin toxicity.
### Monitoring
* Serum potassium levels.
* ECG for signs of hyperkalemia (peaked T waves, widened QRS).
* Renal function.
* Fluid and electrolyte balance.
* Signs and symptoms of hypokalemia and hyperkalemia.
### Clinical Pearls
* Oral potassium chloride should be taken with meals or food to minimize gastrointestinal upset.
* Dilute oral liquid preparations before administration.
* Never administer IV potassium chloride undiluted or as an IV push.
* Close monitoring is essential, especially in patients with renal impairment, cardiovascular disease, or those receiving other medications that affect potassium levels.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and institutional protocols for definitive patient care decisions.*
